TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| Regeneron Serves Up Positive News on Antibody Results The Burrill Report submits: By Michael FitzhughRegeneron (REGN) delivered encouraging news to investors bullish on the company. One of its experimental drugs appeared to significantly lower cholesterol while another successfully reduced pain in osteorarthritis patients. However, that same experimental drug failed to show benefit in patients with acute sciatica. Both drugs are partnered with Sanofi (SNY) and are produced by mice engineered to generate fully human monoclonal antibodies. Complete Story » seekingalpha.com |
J&J to Keep Tylenol Plant Shut to Correct Problems Johnson & Johnson told regulators how it plans to correct problems at a Tylenol plant, and said the plant might remain closed well into next year. online.wsj.com |
Big Pharma Won't Wait in Rush for Biotech's Drugs Rising pressure to find new products is prompting big pharmaceutical companies to license or acquire biotechnology companies' experimental medicines when they've barely been tested in human trials. online.wsj.com |
Indonesia Fines Pfizer Indonesia's antitrust agency fined Pfizer, holding that it violated monopoly regulations on antihypertension products. online.wsj.com |
Exelixis Deepens Profitable Ties to BMS The Burrill Report submits: By Michael FitzhughBristol-Myers Squibb (BMY) will pay Exelixis (EXEL) $60 million as part of two new agreements the partners established to address diabetes and inflammatory diseases. With milestones, Bristol could pay Exelixis $505 million more, plus royalties and other sales-related payments related to the two agonists, drugs that bind to cell receptors and trigger a response in the cell. Complete Story » seekingalpha.com |